Posaconazole

Posaconazole (CAS 171228-49-2), also referenced in development literature as SCH 56592, is a broad-spectrum triazole antifungal active pharmaceutical ingredient marketed under the brand name Noxafil.

It targets invasive fungal infections caused by Aspergillus and Candida species, positioning it as a critical API in antifungal therapy manufacturing for global pharmaceutical supply chains.

Posaconazole is formulated into oral suspensions, delayed-release tablets, and intravenous solutions for prophylaxis and treatment of invasive fungal infections in immunocompromised patients.

Pharmaceutical manufacturers source it as an API for finished dosage form production under GMP conditions. In biotechnology, it is used as a reference standard for antifungal susceptibility testing.

Contract development organizations also use this compound in formulation development work targeting improved bioavailability delivery systems and advanced drug interaction studies in clinical research.

The product is supplied as a white to off-white crystalline powder. It is available in research-grade and GMP-compliant pharmaceutical-grade specifications to meet the requirements of regulated drug manufacturing.

Our material meets rigorous quality standards including USP and EP requirements. Quantities range from small research lots through commercial-scale API batches for industrial use.

Documentation packages including CoA, impurity profiles, and regulatory support files are available upon request to ensure full compliance with international pharmaceutical manufacturing protocols.